AAV mediated PRPF-31 gene therapy(Biogen/Massachusetts Eye and Ear)

N/A

Report date: 2023/10/26 16:51:11

Base Information

Drug NameAAV mediated PRPF-31 gene therapy(Biogen/Massachusetts Eye and Ear)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transference
TargetsNot applicable
Therapy Area/IndicationsRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts Eye And Ear
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts Eye And Ear
Inactive CompaniesN/A
Active IndicationsRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A